Marvel Biosciences announces positive results from preclinical Fragile X study conducted through the FRAXA Drug Validation Initiative

Marvel Biosciences Corp., and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum

To access the full article, please log in or subscribe.